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S296 Poster Session Iwhere the next most common toxicities. Solitary cases of cardiotox-
icity, renal dysfunction, and orthostatic hypotension were observed.
Conclusion: Based on this small cohort of relapsed, transplant
eligible MM patients, DPACE appears to be safe and effective
salvage therapy that may serve as a bridge to ASCT. Ongoing
work is being performed to compare the effectiveness of this reg-
imen with other salvage therapies used in a similar population of
MM patients and to measure progression free and overall survival
after treatment.248
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Background: About 1/3 of advanced Hodgkin lymphoma (HL) pa-
tients fail first line therapy and are candidates for autologous stem
cell transplantation (ASCT). Surveillance, Epidemiology and End
Results (SEER) data indicates a bi-modal age distribution and supe-
rior survival among children/adolescents with HL (Bazzeh 2010).
The aim of this study was to analyze the impact of age on overall sur-
vival (OS) among patients with relapsed/refractory HL undergoing
ASCT. We hypothesized that 1) HL patients undergoing ASCT
have a bi-modal age distribution; 2) the older age cohort has inferior
OS after ASCT.
Patients andMethods:We performed an IRB approved, retrospec-
tive analysis of a combined cohort of 131 adult and pediatric HL pa-
tients undergoing ASCT at Emory University from 1995 to 2011.
The cohort included 54% male, 65% Caucasians, and 26% African
American patients. OS was compared using Kaplan Meier estimates
for the time-to-event analysis and log rank test. Univariate and mul-
tivariate Cox proportional hazards models were used to test our hy-
potheses.
Results: Hypothesis 1: Two age cohorts of HSCT patients were
identified: younger (#35 years, n 5 96) and older (.35 years old,
n5 35), based on a bimodal distribution similar to SEER incidence.
Hypothesis 2: Univariate analysis showed a significantly higher post-
transplant mortality (p5 0.004) for patients.35 compared to those
#35 years. Multivariate analysis, adjusting for gender, race, histol-
ogy, disease status at transplant and stage, showed a hazard ratio of
2.4 for patients.35 years compared to those#35 years of age. His-
tology was similar across the age groups, with 75% patients having
nodular sclerosing histology.
Conclusions:Our analysis showsmarkedly inferiorOS among older
patients with undergoing ASCT.The age related differences in post-
transplant survival were not explained by the decreased actuarial life
expectancy of older subjects based upon life-table projections of sur-
vival for the general population.While there were differences in sup-
portive care, toxicity from treatments, and co-morbid diseases
among older HL patients undergoing ASCT compared with youn-
ger HL patients, the inferior survival of older HL patients undergo-
ing ASCT suggests that theremay be differences in the biology of the
disease based upon the age at which HL is diagnosed. Alternative
strategies for autologous transplantation of older patients with re-
lapsed/refractory HL are needed.249
EPIGENETIC CHANGES ENHANCE THE CYTOTOXICITY OF COMBINED
NUCLEOSIDE ANALOG-DNA ALKYLATING AGENTS IN LYMPHOMA CELLS
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Champlin, R.E.1, Andersson, B.S.1 1UT MD Anderson Cancer Center,
Houston, TX; 2Cross Cancer Institute, Edmonton, AB, CanadaLymphomas are heterogeneous diseases that require combination
therapy for an effective control. A sizable fraction of patients still fail
to respond, or suffer progressive disease, after initially responding to
treatment. In this setting, hematopoietic stem cell transplantation
(HSCT) has been effective particularly in patients who respond to
salvage chemotherapy. In an attempt to design more efficacious
and safe pre-HSCT conditioning treatment, we expanded our
previous observation on the synergistic cytotoxicity of nucleoside-
analog-(NA) andDNA alkylating agent (AA) and investigated the in-
teractions between AAs busulfan (Bu) and melphalan (Mel) and NA
gemcitabine (Gem) in human lymphoma cell line J45.01. We used
IC10 drug concentrations (57 mM Bu, 1 mM Mel and 0.02 mM
Gem) which individually did not have significant effects on cell pro-
liferation. However, their combination resulted in 50% inhibition of
proliferation. Reduction to almost half (20 mM Bu, 0.7 mMMel and
0.01 mM Gem) did not result in inhibition of cell proliferation. Ad-
dition of 0.6 mM suberoylanilide hydroxamic acid (SAHA) to the lat-
ter combination resulted in 65% inhibition of proliferation. The
synergistic cytotoxicity of [Bu+Mel+Gem+SAHA] combinations
correlates with the activation of the ATM-CHK2 pathway, phos-
phorylaton of KAP1, epigenetic changes such as methylation and
acetylation of histone 3, and activation of apoptosis. We deduce
that chromatin alterations mediated by Gem and SAHA may make
genomic DNAmore accessible to DNA alkylation by Bu andMel re-
sulting in increased DNA lesions and commitment of cells to apo-
ptosis. The relevance of epigenetic changes in this drug exposure is
further shown by the induction of expression of DNA methyltrans-
ferases in lymphoma (and leukemia) cells, which have low constitu-
tive levels of DNMT3A and DNMT3B proteins. The addition of
5-aza-2’-deoxycytidine (DAC) to [Bu+Mel+Gem+SAHA] further
enhances cell killing.Our results suggest that epigenetic changesme-
diated by Gem, SAHA and DAC alter chromatin structure and en-
hance DNA alkylation with Bu and Mel. Such effects are further
aggravated by the ability of Gem to inhibit ribonucleotide reductase
andDNA repair. In summary, this study expands our previous obser-
vation of NA-mediated synergistic toxicity mediated by AAs, and
provides a basis to justify future mechanism-based clinical trials us-
ing [Bu+Mel+Gem+SAHA] as pre-HSCT conditioning for patients
with chemotherapy-refractory lymphoma.250
IMPROVED OUTCOME OF AFRICAN AMERICAN MULTIPLE MYELOMA PA-
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African Americans (AA) have twice the risk of developing mul-
tiple myeloma (MM) and, in prior studies, a higher mortality rate
when compared to non-African Americans (non-AA). Novel
agents, such as thalidomide, lenalidomide and bortezomib have
improved the outcome of MM patients but the impact of these
new therapies in AA patients has not been evaluated. In this
study, 53 consecutive patients (23 AA, 30 non-AA) with newly di-
agnosed MM were retrospectively analyzed after induction treat-
ment incorporating a novel agent. AA and non-AA patients were
comparable for age, immunoglobulin isotype, stage of disease, se-
rum albumin level, and cytogenetic abnormalities including del13
(27% vs. 38%, respectively, p 5 NS). Median serum level of a^2
microglobulin at diagnosis was higher in AA than non-AA (5.9
mg/L vs. 3.5 mg/L, p 5 0.024). Using the international uniform
criteria, response rates to induction therapy were not statistically
different between AA and non-AA: overall response rate (ORR,
91% vs. 77%), complete remission (CR, 22% vs. 27%), very
good partial remission (VGPR, 26% vs. 20%), or partial remis-
sion (PR, 43% vs. 30%). However, rate of progressive disease
was significantly higher in non-AA patients (p 5 0.03). Of 53 pa-
tients, 46 (20 AA, 26 non-AA) received standard high-dose che-
motherapy followed by autologous stem cell transplant (ASCT).
With a median follow-up of 47 months, the ORR to ASCT
was 89% in AA and 85% in non-AA, CR+VGPR rates were
61% in AA and 45% in non-AA (p 5 NS). Disease-free survival
Poster Session I S297(DFS) was 28 months in AA and 17 months in non-AA (p 5
NS). Five patients (all non-AA) died, 4 of 5 due to progression
of disease. Response rates of AA patients treated with novel
agents followed by ASCT were then compared to 38 consecutive
historical AA patients receiving conventional induction chemo-
therapy followed by ASCT at our center. After utilizing novel
agents the ORR in AA patients increased from 56% to 89%
(p 5 0.02). Median DFS also improved from 21 to 28 months
(p 5 0.43). Our findings demonstrate that despite the AA popu-
lation having double the incidence of multiple myeloma, AA pa-
tients respond well to novel agents followed by ASCT. These
results also suggest that differences in long term survival between
AA and non-AA MM patients observed in previous studies could
be due to limited access to care rather than biologic causes.251
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Introduction: Stem cell transplantation (SCT) is a treatment option
for relapsed/refractory Non-Hodgkin’s lymphoma (NHL) patients.
Busulfan, cyclophosphamide, and etoposide (Bu/Cy/VP-16) has
been investigated as a conditioning regimen for allogeneic (alloSCT)
and autologous (auSCT), but its spectrum of early (\1 year) and late
(. 1 year) complications are not well characterized. We investigated
the complications experienced by patients at the Northwestern Uni-
versity transplanted with this regimen.
Methods:We performed a retrospective analysis of all relapsed/re-
fractory NHL patients who received SCT at our center with Bu/Cy/
VP-16 conditioning from 3/2003-6/2011.
Results: 25 patients with relapsed/refractory NHL who had SCT
with Bu/Cy/VP were identified. Median age was 49 (range: 28-
71). 13/25 (52%) patients had alloSCT and 12/25 (48%) had
auSCT. Median follow-up was 12 months (range: 5 days-96
months). Progression free survival was 71 6 10 % (95% confi-
dence interval (CI): 53-95%), overall survival was 77 6 9%
(95% CI: 61-98%), and disease free survival was 85% overall.
At less than 100 days post SCT, 4/25 (16%) patients died, 2 al-
loSCT and 2 auSCT. Causes included progressive disease, sepsis,
and respiratory failure. Peri-transplant morbidity (\100 days
post-transplant) most commonly included neutropenic fever
(22/25, 88%), mucositis (16/25, 64%), and elevated liver enzymes
(19/25, 76%), cardiovascular complications (8/25, 32%), pneumo-
nitis (7/25, 28%), and bacteremia (6/25, 24%). At 1 year follow-
up, 9/21 (43%) had persistently elevated liver enzymes, 8/21
(38%) had pneumonitis, and 2/21 (9.5%) had BOOP. At greater
than 1 year, 3/13 (23%) had persistently elevated liver enzymes
and 3/13 (23%) had BOOP. In the alloSCT population, 10/11
(91%) had acute graft versus host disease (GVHD) and 6/11
(55%) had chronic GVHD.
Conclusions: We conclude that Bu/Cy/VP-16 is a highly effective
conditioning regimen for NHL. Toxicity is not insignificant, as
100 day mortality was 16%. At least 2 of the 4 deaths occurred be-
cause of progressive disease, so selection of patients whose disease
is responsive to pre-transplant therapy would reduce the 100 day
mortality. Common peri-transplant complications included neutro-
penic fever, mucositis, and elevated liver enzymes. Given the high ef-
ficacy of this regimen with moderate long-term toxicity, in
chemotherapy responsive patients it can be considered as a viable
conditioning option prior to SCT.252
MYELOABLATIVE DOSES OF BUSULFAN AND FLUDARABINE AS CONDI-
TIONING FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN NON-
HODGKIN’S LYMPHOMA
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Mortality associated with myeloablative conditioning has limited
its application in non-Hodgkin’s lymphoma (NHL). Myeloablation
with pharmacokinetically-targeted busulfan and fludarabine (t-i.v.
BuFlu) has been shown to be safe and effective in acute leukemia
and MDS, however there is very limited data in lymphoma. We as-
sessed retrospectively the outcomes of a consecutive series of 60 pa-
tients (pts) diagnosed with NHL who underwent allogeneic
hematopoietic cell transplant (allo-HCT) with t-i.v. BuFlu between
12/2004 and 8/2010. Thirty-seven pts weremale andmedian age was
54 yrs (range 27-68 yrs). Histologies included de novo or transformed
diffuse large B-cell lymphoma (DLBCL; n 5 12), follicular lym-
phoma (FL; n5 17), mantle cell lymphoma (MCL; n5 9), lympho-
blastic lymphoma (LBL; n 5 8), peripheral T-cell lymphoma
(PTCL; n 5 13) and marginal zone B-cell lymphoma (n 5 1). Me-
dian number of treatment lines was 3 (range 1-8). Median time
from diagnosis to transplant was 32 months (range 4.5- 177.5
months). At transplant, 28 (47%) pts were in CR, 22 (37%) in PR
and 10 (16%) had SD/PD. Average daily busulfan AUCwas targeted
based on pts age, concurrent comorbidities, or eligibility for a Bu
dose escalation trial: 3500 mmol x min/L in 13 pts, 5300 in 41 pts
and more than 5300 in 6 pts. Rituximab 375 mg/m2 on days +1
and +8 was added in 21 of 49 pts with CD20+ lymphomas. GVHD
prophylaxis included tacrolimus and methotrexate (n 5 39), myco-
phenolate (n 5 8) or sirolimus (n 5 13). Thirty-two pts received
grafts from matched sibling donors, 21 from matched unrelated,
and seven from mismatched (one antigen/allele) unrelated donors.
The cumulative incidence of grade 2-4 and grade 3-4 acute
GVHD at day 100 was 74% and 20% respectively. The cumulative
incidence of moderate-severe chronic GVHD at 2 years was 62%.
Progression free survival (PFS) at 3 years was 47.8% for all pts. Over-
all survival (OS) and CI of relapse at 3 year was 55.2% and 26.9% re-
spectively. OS and PFS were superior for pts with FL and LBL.
Patients in CR at transplant had an OS and CI of relapse at 3 years
of 60.7% and 10.7% respectively. NRM at day 100 and 3 year was
10% and 25.3% for the whole group. Main causes of death were re-
lapse (40%), infection (25%) and GVHD (14%). In conclusion, in
our series outcomes were better in patients with LBL and FL.
NRM was lower than historically reported with BuCy or TBI based
conditioning regimens but relapse continues to be the main cause of
failure.
Table. Progression free survival, Overall survival and Cumu-
lative incidence of relapse and Non-relapse mortality accord-
ing to Histologic Type
Follicular T cell DLBC Mantle Lymphoblastic All
n 5 17 n 5 13 n 5 12 n 5 9 n 5 8 n 5 60PFS
1 yr 70.5 30.7 33.3 55.6 62.5 51.7
3 yr 64.7 23.1 33.3 27.8 62.5 47.8
OS
1 yr 70.5 53.8 41.7 55.6 100 63.2
3 yr 64.7 46.1 41.7 55.6 66.7 55.2
CI RELAPSE
1 yr 5.9 38.5 33.3 22.2 37.5 25.0
3 yr 5.9 46.2 33.3 22.2 37.5 26.9
CI NRM
100 day 11.8 23.1 0 11.1 0 10.0
1 yr 29.4 30.8 33.3 22.2 0 23.3
3 yr 29.4 30.8 33.3 22.2 0 25.3
